“Science and Technology Innovation Board Daily”, March 1 — The main contents of today's Science and Technology Innovation Board Evening Report include: the National Data Administration and three other departments jointly researching and improving the transmission efficiency of the “East Digital and Western Computing” network; Ministry of Industry and Information Technology: China's lithium-ion battery industry continues to grow in 2023; and Guangsheng Pharmaceutical completed Series A financing of 100 million yuan.

[Focus on hot topics]

Newsletters:

Three departments including the National Data Administration jointly study and improve the transmission efficiency of the “East Digital Western Computing” network

The National Data Administration, together with the National Development and Reform Commission and the Ministry of Industry and Information Technology, is focusing on making full use of the transmission efficiency of the “East Digital Western Computing” network, further improving the cost performance of enterprise network transmission, listening to opinions and suggestions from national hub node enterprises, data transmission companies, and telecom operators, etc., and studying the establishment of public transmission channels dedicated to national hub nodes to effectively improve the transmission efficiency of the “East Digital Western Computing” network. In the next step, the National Development and Reform Commission, the National Data Administration, and the Ministry of Industry and Information Technology will guide enterprises such as China Telecom, China Unicom, and China Mobile to step up innovation and exploration. In the near future, they will pilot the opening of “East Digital and Western Computing” “public transmission channels” among some hub nodes to explore the use of various service methods to enhance the level of inclusiveness and ease of use, and effectively enhance the sense of acquisition for business owners.

Ministry of Industry and Information Technology: In 2023, China's lithium-ion battery industry will continue to grow, and the country's total lithium battery production will increase 25% year-on-year

According to data from the Ministry of Industry and Information Technology, in 2023, China's lithium-ion battery industry continued to grow. According to the lithium battery industry specification announcement enterprise information and industry association estimates, the country's total lithium battery output exceeded 940 GWh, an increase of 25% over the previous year, and the total output value of the industry exceeded 1.4 trillion yuan.

Depth:

The latest developments! Implementing diversified payments for innovative pharmaceutical devices in Shanghai has already achieved these results

BYD, Tesla “lead”, and six major brands to follow up the “price war” in March

Over 8 billion! “Chuangchuang 2nd Generation” Zhiji Auto has been funded again

[Science and Technology Innovation Board Announcement]

Tuojing Technology and Narui Radar plan to repurchase shares

Tuojing Technology announced that it plans to repurchase shares for 120 million yuan to 197 million yuan, with a repurchase price of no more than 270 yuan/share.

NARI Radar announced that Bao Xiaojun, the company's actual controller, chairman and general manager, proposed that the company use 15 million yuan to 30 million yuan to buy back shares for share incentives or employee stock ownership plans.

Zhenyou Technology: Signed US$112 million daily operating contract

Zhenyou Technology announced that the company recently received a contract for the purchase and sale of a satellite communication project in a certain country signed by the company as a participant with a customer in Beijing. The total contract price was 112 million US dollars (excluding tax).

Yuekang Pharmaceutical: New marketing applications for Tongluo Brain Health Tablets and Zihuawen Lung Relief Granules were accepted

Yuekang Pharmaceutical announced that its subsidiary Guangzhou Yuekang Biopharmaceutical Co., Ltd. received the “Notice of Acceptance” approved and issued by the State Drug Administration, and the company's application for a new drug marketing license for Tongluo Brain Health tablets was accepted. The subsidiary Guangzhou Yuekang Biopharmaceutical Co., Ltd. received the “Notice of Acceptance” approved and issued by the State Drug Administration, and the new drug marketing license application for the company's product Zihuawen lung relief granules was accepted.

Yuandong Biology: Naburpine hydrochloride injection obtained drug registration certificate

Yuandong Biotech announced that naburpine hydrochloride injection has obtained a drug registration certificate.

[Venture capital weather vane]

Dongfang Fuhai exclusively invested in Guangsheng Pharmaceutical to complete Series A financing of 100 million yuan

Recently, Shanghai Guangsheng Pharmaceutical Co., Ltd. successfully completed Series A financing of 100 million yuan. This round of financing is exclusively invested by Dongfang Fuhai. The financing will be used to accelerate the company's new product development and commercialization of the first product in the field of photodynamic therapy.

China Mobile's fund participated in investing in Lianhui Technology to complete a new round of strategic financing of hundreds of millions of yuan

Recently, Lianhui Technology announced the completion of a new round of strategic financing of hundreds of millions of yuan. The investors are composed of leading state-owned and market-based institutions such as China Mobile Industry Chain Development Fund, Zhongyuan Qianhai Fund under Qianhai Fangzhou (Qianhai Mother Fund Management Agency), and the Qilu Qianhai Fund. According to reports, this round of financing will mainly be used for technology research and development, product innovation, and market expansion of multi-modal large models and autonomous agents.